Hence, targeting these enzymes by PDE-5 inhibitors or sGC stimulators/activators could induce dilation of hepatic sinusoids, decrease intrahepatic resistance, increase portal venous blood flow, and consequently, lower portal pressure in cirrhotic portal hypertension. The gene discussed is SGCB; the disease is liver disorder.